Top Tweets for #RateCutEnvironment

almost 2 years ago

$BLUE $PFE $HTGC #BlueBirdBio #BioTech #SickleCell #Mergers #Acquisitions #Disease #Drugs #RateCutEnvironment #SmallCaps $XBI $IBB $SPY $QQQ $IWM $IWN $HTGC Loan Agreement with $BLUE $BlueBirdBio via MileStone payouts. Renegotiated certain terms of its loan agreement with Hercules Capital, Inc. $HTGC and is eligible to receive two future tranches totaling $50 million. contingent upon achievement of patient start and product delivery milestones and completion of additional financing. $BalanceSheet Cash Position: $193M Cash Runway into Q2 2025 with two MileStone payouts of $50M by 2024 year end if it meets its 2024 guidance.

RisenFit

@risenfit

almost 2 years ago

$BLUE #BioTech #SickleCell #Medicaid #BlueBirdBio #MergersAndAcquisitions Consolidating price action. 1 hour & 4 hour. $BLUE $PFE $SPY $QQQ $IBB $XBI $IWM $IWN $PFE Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4B buyout of Global Blood Therapeutics in 2022. $PFE said on Wednesday it was withdrawing its #SickleCell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication & deaths. https://t.co/MQ8JFms9cR #Notes Pfizer $PFE has been exploring other treatments for sickle cell disease, but with the withdrawal of Oxbryta (voxelotor), the immediate options within their portfolio are limited. Oxbryta was the only drug $PFE had in the #SickleCell Space. $BLUE #BlueBirdBio Updates. Current as of August 14, 2024: 1. #2024Guidance The Company anticipates approximately 85 patient starts (cell collections) in 2024 combined across its portfolio of three FDA approved therapies 👉LYFGENIA: Approved for #SickleCell ZYNTEGLO: Approved for the treatment of beta-thalassemia in patients who require regular blood transfusions. SKYSONA: Approved for the treatment of cerebral adrenoleukodystrophy (CALD), a rare neurological disorder affecting boys. 2. #SickleCell Successfully completed manufacturing and release testing for first commercial LYFGENIA patient and the first infusion is being scheduled. 3. Rapid acceleration projected for ZYNTEGLO following the recent approval of additional manufacturing capacity. https://t.co/b8RVg0cYk2

Top Tweets for #RateCutEnvironment

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users